Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.76 |
| ▸ | CA1 | P00915 | 15/20 | 0.76 |
| ▸ | CA2 | P00918 | 15/20 | 0.76 |
| ▸ | CA12 | O43570 | 7/20 | 0.76 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.72 |
| ▸ | CA7 | P43166 | 2/20 | 0.72 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151146 | 0.91 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21728989 | 0.91 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL20622624 | 0.91 | CA9 (0.75) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17049667 | 0.90 | CA9 (0.74) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12185092 | 0.89 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14089616 | 0.89 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL22855043 | 0.89 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21282083 | 0.89 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21183301 | 0.89 | CA1 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17245251 | 0.89 | CA1 (0.70) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9488660-B2 | Methods and compositions comprising non-natural amino acids | AMBRX, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2339014-A1 | Methods and compositions comprising non-natural amino acids | AMBRX, INC. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110144307-A1 | Methods and Compositions Comprising Non-Natural Amino Acids | AMBRX, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090018029-A1 | Methods and Compositions Comprising Non-Natural Amino Acids | AMBRX, INC. (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144307-A1 | Methods and Compositions Comprising Non-Natural Amino Acids | PTMS, NPPA, DNPEP | CA9 1526/4885CA1 1120/4885CA2 2937/4885 |
| US-20090018029-A1 | Methods and Compositions Comprising Non-Natural Amino Acids | PTMS, NPPA, DNPEP | CA9 1526/4885CA1 1120/4885CA2 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.